Luke S Howard

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8532347/publications.pdf

Version: 2024-02-01

114 papers	10,812 citations	53660 45 h-index	31759 101 g-index
121 all docs	121 docs citations	121 times ranked	11542 citing authors

#	Article	IF	Citations
1	Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2009, 30, 2493-2537.	1.0	3,108
2	Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 790-796.	2.5	483
3	Whole-genome sequencing of patients with rare diseases in a national health system. Nature, 2020, 583, 96-102.	13.7	338
4	Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy. Circulation, 2016, 133, 1761-1771.	1.6	307
5	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nature Communications, 2018, 9, 1416.	5.8	279
6	Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. European Heart Journal, 2021, 42, 1866-1878.	1.0	274
7	Treatment Goals of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D73-D81.	1.2	250
8	Relating oxygen partial pressure, saturation and content: the haemoglobinâ€“oxygen dissociation curve. Breathe, 2015, 11, 194-201.	0.6	239
9	An official European Respiratory Society statement: pulmonary haemodynamics during exercise. European Respiratory Journal, 2017, 50, 1700578.	3.1	222
10	Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension. Circulation, 2008, 117, 3020-3030.	1.6	208
11	Iron Deficiency and Raised Hepcidin in Idiopathic Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2011, 58, 300-309.	1.2	208
12	Evidence of Dysfunction of Endothelial Progenitors in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 780-787.	2.5	206
13	Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Science Translational Medicine, 2017, 9, .	5.8	206
14	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respiratory Medicine,the, 2017, 5, 785-794.	5.2	201
15	Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. Echo Research and Practice, 2018, 5, G11-G24.	0.6	174
16	Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart, 2011, 97, 1054-1060.	1.2	154
17	Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. Circulation, 2017, 135, 460-475.	1.6	154
18	Reduced MicroRNA-150 Is Associated with Poor Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 294-302.	2.5	153

#	Article	IF	Citations
19	Echocardiographic assessment of pulmonary hypertension: standard operating procedure. European Respiratory Review, 2012, 21, 239-248.	3.0	146
20	Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure. Circulation, 2020, 141, 678-693.	1.6	139
21	Pulmonary arterial hypertension: the burden of disease and impact on quality of life. European Respiratory Review, 2015, 24, 621-629.	3.0	128
22	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	5.2	122
23	Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives. European Respiratory Review, 2013, 22, 535-542.	3.0	120
24	Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. Lancet Respiratory Medicine,the, 2021, 9, 107-116.	5.2	119
25	Simvastatin as a Treatment for Pulmonary Hypertension Trial. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1106-1113.	2.5	112
26	ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1800332.	3.1	110
27	Heterogeneity in Lung ¹⁸ FDG Uptake in Pulmonary Arterial Hypertension. Circulation, 2013, 128, 1214-1224.	1.6	107
28	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respiratory Medicine,the, 2017, 5, 717-726.	5.2	99
29	Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. European Respiratory Journal, 2011, 38, 1453-1460.	3.1	97
30	Differences in Ventilatory Inefficiency Between Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. Chest, 2011, 140, 1284-1291.	0.4	93
31	Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. European Respiratory Journal, 2011, 37, 813-822.	3.1	85
32	The importance of patient perspectives in pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801919.	3.1	85
33	Intravenous Iron Therapy in Patients with Idiopathic Pulmonary Arterial Hypertension and Iron Deficiency. Pulmonary Circulation, 2015, 5, 466-472.	0.8	79
34	Risk Stratification of Patients With Acute Symptomatic Pulmonary Embolism Based on Presence or Absence of Lower Extremity DVT. Chest, 2016, 149, 192-200.	0.4	76
35	Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. Journal of Heart and Lung Transplantation, 2017, 36, 770-779.	0.3	73
36	Human PAH is characterized by a pattern of lipid-related insulin resistance. JCI Insight, 2019, 4, .	2.3	69

#	Article	IF	Citations
37	Use of vasopressin after Caesarean section in idiopathic pulmonary arterial hypertension. British Journal of Anaesthesia, 2007, 99, 552-555.	1.5	67
38	Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease. European Respiratory Review, 2011, 20, 236-242.	3.0	67
39	Aberrant Chloride Intracellular Channel 4 Expression Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 1770-1780.	1.6	63
40	Microbiological profile of community-acquired pneumonia in adults over the last 20 years. Journal of Infection, 2005, 50, 107-113.	1.7	61
41	Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology, 2014, 53, 285-292.	0.9	56
42	NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing. Thorax, 2013, 68, 391-393.	2.7	53
43	Safety of sapropterin dihydrochloride (6râ€“bh4) in patients with pulmonary hypertension. Experimental Lung Research, 2011, 37, 26-34.	0.5	49
44	British Thoracic Society emergency oxygen audits. Thorax, 2011, 66, 734-735.	2.7	48
45	Morphologic and Functional Remodeling of the Right Ventricle in Pulmonary Hypertension by Real Time Three Dimensional Echocardiography. American Journal of Cardiology, 2012, 109, 906-913.	0.7	47
46	Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1). JACC: Cardiovascular Interventions, 2020, 13, 989-999.	1.1	47
47	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 586-594.	2.5	45
48	Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery: a systematic review and expert consensus statement. British Journal of Anaesthesia, 2021, 126, 774-790.	1.5	45
49	Initial oxygen management in patients with an exacerbation of chronic obstructive pulmonary disease. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 499-504.	0.2	44
50	Right atrial flutter isthmus ablation is feasible and results in acute clinical improvement in patients with persistent atrial flutter and severe pulmonary arterial hypertension. International Journal of Cardiology, 2011, 149, 279-280.	0.8	42
51	Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension. American Journal of Cardiovascular Drugs, 2008, 8, 171-185.	1.0	41
52	Connective tissue disease-associated pulmonary arterial hypertension. F1000prime Reports, 2015, 7, 06.	5.9	41
53	Patient engagement and self-management in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 399-407.	3.0	39
54	Sirolimus-Induced Pulmonary Hypersensitivity Associated With a CD4 T-Cell Infiltrate. Chest, 2006, 129, 1718-1721.	0.4	38

#	Article	IF	Citations
55	Echocardiographic Screening for Pulmonary Hypertension in CongenitalÂHeart Disease. Journal of the American College of Cardiology, 2018, 72, 2778-2788.	1.2	38
56	Pulmonary arterial hypertension exacerbated by ruxolitinib. Haematologica, 2015, 100, e244-e245.	1.7	37
57	Pulmonary veno-occlusive disease presenting with recurrent pulmonary oedema and the use of nitric oxide to predict response to sildenafil. Thorax, 2008, 63, 933-934.	2.7	34
58	Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension. Thorax, 2019, 74, 380-389.	2.7	34
59	The ADAMTS13â€“VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801805.	3.1	31
60	Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. European Respiratory Journal, 2022, 59, 2002463.	3.1	31
61	The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension. Thorax, 2017, 72, 1035-1045.	2.7	30
62	A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. EBioMedicine, 2021, 69, 103444.	2.7	30
63	Right ventricular function in patients with pulmonary hypertension; the value of myocardial performance index measured by tissue Doppler imaging. European Journal of Echocardiography, 2010, 11, 719-724.	2.3	29
64	Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2021, 14, .	1.6	29
65	EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. European Respiratory Journal, 2021, 57, 2000124.	3.1	29
66	The association between tricuspid regurgitation velocity and 5â€year survival in a <scp>N</scp>orth <scp>W</scp>est <scp>L</scp>ondon population of patients with sickle cell disease in the <scp>U</scp>nited <scp>K</scp>ingdom. British Journal of Haematology, 2013, 162, 400-408.	1.2	28
67	New therapeutic agents for pulmonary vascular disease. Paediatric Respiratory Reviews, 2005, 6, 285-291.	1.2	26
68	Exertional dyspnoea in pulmonary arterial hypertension. European Respiratory Review, 2017, 26, 170039.	3.0	25
69	Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 57, 2003201.	3.1	25
70	Cardiopulmonary Exercise Testing Demonstrates Maintenance of Exercise Capacity in Patients With Hypoxemia and Pulmonary Arteriovenous Malformations. Chest, 2014, 146, 709-718.	0.4	24
71	TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. Pulmonary Circulation, 2021, 11, 1-7.	0.8	24
72	Exercise physiological responses to drug treatments in chronic thromboembolic pulmonary hypertension. Journal of Applied Physiology, 2016, 121, 623-628.	1.2	22

#	Article	IF	Citations
73	Acute pulmonary embolism. Clinical Medicine, 2019, 19, 243-247.	0.8	22
74	Response to Pulmonary Arterial Hypertension Drug Therapies in Patients with Pulmonary Arterial Hypertension and Cardiovascular Risk Factors. Pulmonary Circulation, 2014, 4, 669-678.	0.8	21
75	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nature Communications, 2021, 12, 7104.	5.8	21
76	Developments in the management and treatment of pulmonary embolism. European Respiratory Review, 2015, 24, 484-497.	3.0	20
77	Rebound hypoxaemia after administration of oxygen in an acute exacerbation of chronic obstructive pulmonary disease. BMJ: British Medical Journal, 2011, 342, d1557-d1557.	2.4	19
78	Lung Function, Inflammation, and Endothelinâ€1 in Congenital Heart Diseaseâ€“Associated Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2018, 7, .	1.6	17
79	British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism. BMJ Open Respiratory Research, 2018, 5, e000281.	1.2	16
80	Idiopathic pulmonary arterial hypertension and coâ€existing lung disease: is this a new phenotype?. Pulmonary Circulation, 2020, 10, 1-8.	0.8	16
81	Emerging therapies for pulmonary arterial hypertension. Expert Opinion on Investigational Drugs, 2007, 16, 803-818.	1.9	14
82	Global Right Heart Assessment with Speckle-Tracking Imaging Improves the Risk Prediction of a Validated Scoring System in Pulmonary Arterial Hypertension. Journal of the American Society of Echocardiography, 2020, 33, 1334-1344.e2.	1.2	14
83	Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2022, 41, 780-790.	0.3	13
84	Physiciansâ€™ and patientsâ€™ expectations of therapies for pulmonary arterial hypertension: where do they meet?. European Respiratory Review, 2014, 23, 458-468.	3.0	12
85	Resting right ventricular function is associated with exercise performance in PAH, but not in CTEPH. European Heart Journal Cardiovascular Imaging, 2018, 19, 185-192.	0.5	12
86	Last call for the flight simulation test?. European Respiratory Journal, 2013, 42, 1175-1177.	3.1	11
87	Management of pulmonary arterial hypertension in patients aged over 65 years. European Heart Journal Supplements, 2019, 21, K29-K36.	0.0	9
88	Autoimmunity Is a Significant Feature of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 81-93.	2.5	9
89	Left Main Bronchus Compression Due to Main Pulmonary Artery Dilatation in Pulmonary Hypertension: Two Case Reports. Pulmonary Circulation, 2015, 5, 723-725.	0.8	8
90	Oxygen therapy. Clinical Medicine, 2009, 9, 156-159.	0.8	7

#	Article	IF	Citations
91	Outpatient management of pulmonary embolism. Lancet, The, 2011, 378, 5-6.	6.3	7
92	Is right heart catheterisation still a fundamental part of the follow-up assessment of pulmonary arterial hypertension? The argument against. European Respiratory Journal, 2018, 52, 1800996.	3.1	7
93	Combination therapy in pulmonary arterial hypertension: do we have the right strategy?. Expert Review of Respiratory Medicine, 2011, 5, 191-205.	1.0	6
94	An audit of hypoxaemia, hyperoxaemia, hypercapnia and acidosis in blood gas specimens. European Respiratory Journal, 2012, 39, 219-221.	3.1	6
95	Right ventriculoâ€“arterial uncoupling and impaired contractile reserve in obese patients with unexplained exercise intolerance. European Journal of Applied Physiology, 2018, 118, 1415-1426.	1.2	6
96	Maintain normoxaemia until more evidence is available. BMJ: British Medical Journal, 2010, 341, c3715-c3715.	2.4	6
97	Reduced Confounding by Impaired Ventilatory Function With Oxygen Uptake Efficiency Slope and VE/VCO‹sub›2‹/sub› Slope Rather Than Peak Oxygen Consumption to Assess Exercise Physiology in Suspected Heart Failure. Congestive Heart Failure, 2010, 16, 259-264.	2.0	5
98	Power of resting echocardiographic measurements to classify pulmonary hypertension patients according to European society of cardiology exercise testing risk stratification cut-offs. International Journal of Cardiology, 2018, 257, 291-297.	0.8	5
99	BTS guidelines for the initial outpatient management of pulmonary embolism: thereâ€™s no place like home. Thorax, 2018, 73, 607-608.	2.7	5
100	Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and singleâ€arm efficacy. Pulmonary Circulation, 2021, 11, 1-12.	0.8	5
101	Thrombolytic therapy for submassive pulmonary embolus? PRO viewpoint. Thorax, 2014, 69, 103-105.	2.7	4
102	Large granular lymphocyte leukaemia. British Journal of Hospital Medicine (London, England: 2005), 2005, 66, 364-365.	0.2	3
103	Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?. Expert Review of Respiratory Medicine, 2018, 12, 387-402.	1.0	3
104	Response to Letter Regarding Article, â€œCirculating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertensionâ€• Circulation, 2009, 119, .	1.6	2
105	How to assess the dangers of hyperoxemia: methodological issues. Critical Care, 2011, 15, 435.	2.5	2
106	Thrombolysis for PE: less is more?. Thorax, 2018, 73, 412-413.	2.7	2
107	BTS clinical statement for the assessment and management of respiratory problems in athletic individuals. Thorax, 2022, 77, 540-551.	2.7	2
108	ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. ERJ Open Research, 2022, 8, 00665-2021.	1.1	2

#	Article	IF	Citations
109	Pulmonary vascular disease: pulmonary thromboembolism and pulmonary hypertension. Medicine, 2012, 40, 214-220.	0.2	1
110	Cardiopulmonary Exercise Testing. Pulmonary Medicine, 2012, 2012, 1-3.	0.5	0
111	Authorsâ€™ response to: How should we best determine the need for in-flight oxygen in patients with pulmonary arterial hypertension. Thorax, 2013, 68, 680.2-681.	2.7	0
112	125â€…Deterioration of Right Ventricular Function on Exercise Detected by Exercise Cardiac Magnetic Resonance Imaging in Patients with Pulmonary Arterial Hypertension. Heart, 2016, 102, A88-A89.	1.2	0
113	Abstract 202: The Role of Neutrophil Extracellular Traps in the Pathogenesis of Pulmonary Hypertension.. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	1.1	0
114	150â€ƒIncremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension. European Heart Journal Supplements, 2021, 23, .	0.0	0